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Enhancement of Regression of
Cervical Intraepithelial
Neoplasia II (Moderate
Dysplasia) With Topically
Applied All-frans-Retinoic
Acid: a Randomized Trial
Frank L. Meyskens, Jr., Earl
Surwit, Thomas E. Moon, Joel M.
Childers, John R. Davis, Robert
T. Dorr, Cynthia S. Johnson,
David S. Alberts*
Background: Retinoids enhance dif-
ferentiation of most epithelial tissues.
Epidemiologic studies have shown an
inverse relationship between dietary
intake or serum levels of vitamin A and
the development of cervical dysplasia
and/or cervical cancer. Pilot and phase
1 investigations demonstrated the feas-
ibility of the local delivery of aW-trans-
retinoic acid (RA) to the cervix using a
collagen sponge insert and cervical cap.
A phase II trial produced a clinical
complete response rate of 50%. Pur-
pose: This randomized phase III trial
was designed to determine whether
topically applied RA reversed mod-
erate cervical intraepithelial neoplasia
(CIN) II or severe CIN. Methods:
Analyses were based on 301 women
with CIN (moderate dysplasia, 151
women; severe dysplasia, 150 women),
evaluated by serial colposcopy, Papa-
nicolaou cytology, and cervical biopsy.
Cervical caps with sponges containing
either 1.0 mL of 0.372% $-trans-RA or
a placebo were inserted daily for 4 days
when women entered the trial, and for
2 days at months 3 and 6. Patients
receiving treatment and those receiving
placebo were similar with respect to
age, ethnicity, birth-control methods,
histologic features of the endocervical
biopsy specimen and koilocytotic
atypia, and percentage of involvement
of the cervix at study. Treatment ef-
fects were compared using Fisher's
exact test and logistic regression
methods. Side effects were recorded,
and differences were compared using
Fisher's exact test. Results: RA in-
creased the complete histologic regres-
sion rate of CIN II from 27% in the
placebo group to 43% in the retinoic
acid treatment group (P = .041). No
treatment difference between the two
arms was evident in the severe dys-
plasia group. More vaginal and vulvar
side effects were seen in the patients
receiving RA, but these effects were
mild and reversible. Conclusions: A
short course of locally applied RA can
reverse CIN II, but not more advanced
dysplasia, with acceptable local side ef-
fects. Implications: A derivative of
vitamin A can reverse or suppress an
epithelial preneoplasia, lending further
support to the notion that chemo-
prevention of human cancer is feasible.
[J Natl Cancer Inst 86:539-543,1994]
Vitamin A and its natural and synthetic
derivatives (retinoids) are potent stimu-
lators of cellular response and affect the
biological function of a diversity of or-
gans and tissues (/). Both in vitro and in
vivo, retinoids modulate the growth of
normal epithelial cells, in general slowing
or inhibiting proliferation and enhancing
differentiation and maturation of cells and
tissues (2^). A large number of epidemi-
ologic studies have demonstrated a
protective effect of vitamin A against
smoking-related tumors (4) and, in the
last decade, against cervical dysplasia and
cancer (5). These observations supported
the notion that vitamin A may affect the
natural history of cervical intraepithelial
neoplasia (CIN) and cervical malignancy.
We have conducted a series of preclini-
cal studies and phase I and II trials (6-JO)
in CIN and demonstrated the feasibility
of chemoprevention of cervical cancer.
Our initial studies were directed to devel-
oping an optimal local delivery device to
the cervix for all-rrans-retinoic acid
(RA). The device consisted of a cervical
cap and collagen sponge insert within
which the RA was placed (6,7,11). A
phase I trial was done, and a toxic dose
was defined (S). Based on this ex-
perience, the next lower dose, which was
well tolerated, was chosen for use in a
subsequent phase II investigation. The
distribution of responses in the phase I
study suggested a dose-response effect
(9). A phase II trial among 20 patients
demonstrated an encouraging complete
clinical response rate of 50% in CIN (70).
On the basis of these results, we designed
a randomized phase III trial of topical RA
in placebo cream versus placebo cream in
patients with moderate and severe cervi-
cal dysplasia.
Patients and Methods
Patient Eligibility
Criteria for eligibility were as follows: (a) biop-
sy-proven moderate or severe dysplasia; (ft) com-
plete colposcopic delineation of the lesion after
biopsy specimens were taken; (c) endocervical
curettage negative for severe dysplasia, carcinoma
in situ, or invasive carcinoma of the cervix; and (d)
negative pregnancy test and plan not to become
pregnant while under treatment. All patients
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received oral contraceptives, used an intrauterine
device, or were placed on an effective form of bar-
rier contraception. Patients who had had prior treat-
ment by cauterization, cryosurgery, laser, or
conization were eligible as long as this treatment
was administered 6 or more months prior to study
entry.
Criteria for exclusion included the following: (a)
prior or concomitant genital malignancy, (b) pre-
vious pelvic irradiation, (c) in utero diethylstil-
bestrol exposure, or (d) prior retinoid treatment for
any reason (>25 000 IU vitamin A/d or the
equivalent for 3 months).
Written informed consent was obtained from
each patient in adherence to the guidelines of the In-
stitutional Review Board of the University of
Arizona. All patients were specifically warned of
the potential teratogenic effects of the RA and that
the use of this compound in this manner was ex-
perimental.
Cervical biopsy specimens (and accompanying
Papanicolaou smears) classified at local centers as
moderate or severe squamous dysplasia identified
patients who were potentially eligible for the study.
Entry in the trial occurred only after biopsy confir-
mation by the project pathologist (J. R. Davis). The
confirmation was initiated by the coordinator by
submitting slides and the patient data form with
code number. Slides (biopsy specimens and smears)
were retained in the Department of Pathology for
the duration of the project.
Histologic Classification of Dysplasia
The classification proposed by the World Health
Organization was used (12). The various subgroups
of cervical dysplasia were classified according to 1)
the degree to which the cervical squamous epi-
thelium was replaced by neoplastic cells and 2) the
degree of atypia and maturation. Thus, lesions in
which the neoplastic cells showed minimal atypism
and extended one quarter or one third of the way
from the basal layer to the surface were classified as
mild dysplasia. Lesions in which the neoplastic cells
showed greater atypism and extended through one
half to two thirds of the epithelial layer were clas-
sified as moderate dysplasia, and those involving
three quarters to 90% of the epithelium but showing
some surface maturation were classified as severe
dysplasia. Lesions demonstrating full-thickness re-
placement by neoplastic cells with marked atypism
and no evidence of maturation were classified as
carcinoma in situ; patients with these lesions were
not eligible for study entry.
Histologic description included the following: (a)
the degree of retention of nuclear polarity, based on
the normal tendency of the squamous cells to as-
sume a parallel rather than a perpendicular position
with reference to the basement membrane, graded as
mild, moderate, or marked; (b) the degree of loss of
cellular maturation, based primarily on a nuclear-
cytoplasmic ratio, graded as mild, moderate, or
marked; (c) the presence of so-called "koilocytotic
atypia," characterized by the presence of large cells
with relatively small, irregular hyperchromatic
nuclei and surrounded by clear, transparent cyto-
plasm (this cell has also been referred to as a koilo-
cyte); and (d) extension into endocervical "glands"
also specified and the extent graded as mild, moder-
ate, or marked.
Cytologic description of dysplasia included the
following: (a) mild dysplasia (C1N I)—mature,
polygonal superficial, and intermediate squamous
cells; clean background; small percentage of abnor-
mal cells; nuclei slightly enlarged; and hyper-
chromatic with a finely granular chromatin pattern.
(Nucleoli were not seen.) (b) moderate dysplasia
(CIN II)—clean background; increased number of
abnormal cells; intermediate cells; increased nu-
clear-cytoplasmic ratio; and nuclei hyperchromatic,
usually with a finely granular chromatin pattern.
(Nucleoli were not seen.) (c) severe dysplasia—
clean background; increased number of abnormal
cells, often occurring in sheets but maintaining
definite cytoplasmic borders; immature, round, or
oval parabasal cells; increased nuclear-cytoplasmic
ratio; and increased hyperchromasia with finely
granular chromatin pattern. (Nucleoli were not
seen.)
Biopsy-Cytology Evaluation Reporting
Each biopsy specimen was evaluated separately
by the project pathologist, and a written report with
morphologic description and diagnosis was sent by
the project pathologist to the coordinator. Each
cytology specimen was evaluated separately by the
project pathologist, and the results were also sent to
the coordinator.
A Pathology Data Flow Record was maintained
by the project pathologist. It captured the types of
study (biopsy and cytology), the accession numbers
of the study materials, dates of acquisition and posi-
tion in the study, and diagnoses. In all instances of
persistent dysplasia of moderate or severe degree,
comparisons were made with prior study materials.
The Pathology Data Flow Record captured all path-
ology data for use of review at project completion.
Patients had prestudy Papanicolaou cytology,
colposcopic mapping of the cervix, biopsy of cervi-
cal lesion most involved by colposcopy, complete
blood cell counts, and renal and liver function
studies.
Therapeutic Regimen
Patients were stratified by degree of dysplasia
(moderate or severe). They were randomly assigned
to receive placebo cream or RA in the placebo
cream.
Drug Requirements and Delivery
The drug characteristics and delivery system are
described extensively elsewhere (7J8). The free
chemical and cream-based vehicle were provided by
George Weber (Ortho Pharmaceuticals, Raritan,
N.J.), stored at -20 "C, and protected from light.
RA was dissolved in a proprietary cream-based
vehicle, which contained polyethylene glycol 400,
butylated hydroxytoluene, and 55% alcohol. The
retinoid was incorporated into the cream under spe-
cial minimal UV lighting (Sylvania Red F96T12-R
tubes) to prevent photoisomerization and decom-
position. The uniformity and content of RA were
confirmed by reverse-phase high-pressure liquid
chromatography with the use of a previously pub-
lished assay method (7). The batches of prepared
creams were also negative for endotoxin pyrogens
according to the Limulus amebocyte lysate method
(Pyrogent; Mallinckrodt Inc., St. Louis, Mo.). On
the basis of our phase I trial and acceptable results
with side effects in our phase II study, we selected
1.0 mL of 0.375% RA (0.375 mg RA/100 g of
cream by weight) administered daily as the treat-
ment dose.
Delivery System
The delivery system consisted of a cervical cap
within which a collagen sponge was inserted. The
cervical cap was made of the hydrogel Hypan (Sky
Biopolymers, Princeton, N.J.) which, when in con-
tact with wet tissue surfaces, adheres to them by a
force of differential osmotic pressures. The charac-
teristics and properties of the collagen sponge are
extensively described elsewhere (//). The sponges
were made from pure collagen isolated from bovine
skin, swollen at pH 3.0, and stabilized into the
physical form of a sponge layer. Glutaraldehyde was
used as a cross-linking agent to provide high
resilience and fluid-binding capacity. The average
pore size was 400 A (range, 80-1400 A). The spon-
ges were cut into thin, round wafers approximately
3- to 4-mm thick and 7 mm in diameter.
Schedule of RA Administration
One milliliter of a fresh retinoid preparation was
applied to the sponge, and the sponge-cervical cap
device was carefully inserted by the investigator into
the vaginal vault. The position of the cap around and
against the cervix was documented by clinical ex-
amination. Patients returned daily for removal of the
sponge-cap insert. One milliliter of fresh drug was
applied to a new sponge, and a fresh delivery device
was reapplied. A new collagen sponge-cervical cap
device with RA was inserted daily for 4 days.
Patients returned at 3 and 6 months for follow-up
and for maintenance treatment consisting of RA at a
concentration of 0.372% inserted daily for 2 days.
The frequency and duration of maintenance treat-
ment were selected on the basis of the following fac-
tors (11,13): Two days of treatment was the
minimum time at which cervical changes were evi-
dent; re-treatment for 2 but not for 4 days was ac-
ceptable to most patients; responses in the phase I
trial lasted 3-4 months; and this frequency of re-
treatment was deemed acceptable by most patients
in a poll conducted during planning of the phase II
study. This regimen was subsequently shown to be
acceptable in our phase II trial (10).
The dropout rates during therapy (first 6 months)
were similar in both arms, both for true dropouts and
dropouts for protocol-specified reasons. True
dropouts included 34 patients (22%) in the therapy
arm and 35 patients (23%) in the placebo arm.
Reasons for dropouts were as follows: patient in-
eligible (therapy arm, n = 1; placebo arm, n = 2),
patient refused further follow-up (7,9), patient lost
to follow-up (14,15), physician's decision (2J), and
other reasons (4,5). If severe dysplasia was evident
at any time (including months 3 and 6 of main-
tenance treatment), a biopsy was performed; if the
biopsy was indicative of severe disease, the patient
was removed from the study. Ten patients in the
treatment arm and 21 patients in the placebo arm
had persistent severe biopsy-proven dysplasia at 3 or
6 months, and they were removed from the study.
In addition, the moderate dysplasia progressed in
four patients in the treatment arm to severe biopsy-
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proven dysplasia in the first 6 months, while it did
so in five patients in the control group. No patient
had disease that progressed to carcinoma in situ
during this trial.
Follow-Up
Patients had follow-up at intervals of 9, 12, 15,
21, and 27 months after study initiation with
Papanicolaou smears and colposcopy. At 15 months
(9 months after maintenance treatment), the desig-
nated primary end point of the study, all patients
were evaluated for response by Papanicolaou smear,
colposcopy, and biopsy. Some patients had persist-
ent severe disease at 9 and 12 months and therefore
had had a biopsy and were removed from the study.
If patients missed their 15-month evaluation time
point, they were evaluated at the 21- or 27-month
follow-up point. The study design was to use a
single experienced pathologist (J. R. Davis), who
was blinded to the treatment assignment. Entry
biopsy specimens were compared with interval
biopsy specimens to facilitate recognition of change.
Patients were considered to have achieved a com-
plete response only if the Papanicolaou smear and
the biopsy specimen were negative 15 months after
the start of treatment.
Toxicity
Toxicity was evaluated on days 1 through 4 and
8 of the initial treatment and at the completion of
each maintenance treatment by clinical evaluation,
colposcopy, and colpophotographs.
We have described our system for systemic
toxicity of retinoids elsewhere. Clinical and colpo-
scopic assessments for cervical, vaginal, and vulvar
side effects were evaluated at each visit, as pre-
viously described and summarized below (10). The
adverse local effects were compared in patients
treated with RA and in those treated with placebo
and are as follows: grade 0, none; grade 1+ (mild),
cervical erythema (vaginal burning, irritation, itch-
ing, or discharge not bothersome to patient); grade
2+ (moderate), cervical erythema (vaginal burning,
itching, or irritation bothersome to patient), erythe-
ma or increased vascularity of vaginal mucosa, or
both; and grade 3+ (severe), cervical ulceration
(vaginal burning, itching, irritation, or discharge
leading to discontinuation of treatment), ulceration
or bleeding, or both.
Statistical Considerations
In the analysis, we included all patients with a
follow-up biopsy at 15, 12, 9, 21, or 27 months. The
primary null hypothesis of the study was that there
would be no difference between the retinoid and
placebo groups in the complete biopsy frequency at
15 (or 12, 9, 21, or 27 months) months. We used
Fisher's exact test to compare the frequency of com-
plete biopsy response between groups; complete
response of the follow-up biopsy indicated no
atypia. We also used logistic regression methods to
compare the frequency of response and to simul-
taneously adjust for potential confounding or risk
modification factors, including all characteristics
listed in Table 1, plus treatment by age, treatment by
quadrant, and age by quadrant. The LOGIST proce-
dure in the SAS statistical package was used. Treat-
ment comparisons were based on one-sided tests,
since the hypothesis of increased complete response
and of greater toxicity in the RA treatment arm was
of interest.
Comparisons of toxicity rates between the treat-
ment arms were based on Fisher's exact test. All
eligible patients were included in the analyses of
toxicity.
Results
Patient Characteristics
A total of 301 patients (moderate
dysplasia, 151; severe dysplasia, 150)
from the University of Arizona were
entered in the study and were randomly
assigned to treatment between November
19, 1985, and March 27, 1989. Three
patients (1%) were subsequently found to
be ineligible and did not receive a 15-
month follow-up biopsy; 14 were ex-
cluded by the physician; and 52 were lost
to follow-up, did not receive a follow-up
biopsy, and were excluded from analysis.
Therefore, a total of 69 patients were ex-
cluded from follow-up, leaving 141
patients with CIN II and 99 patients with
CIN HI available for analysis of efficacy.
The treatment arms were fairly well
balanced according to various patient
characteristics including age, ethnicity,
birth-control methods, and prior treatment
(Table 1). Smoking histories of the
patients were not recorded. The distribu-
tion of disease characteristics at study
entry between the two groups as mea-
sured by colposcopic appearance and his-
tologic characterization of the lesion was
equivalent. Colposcopic characteristics
included degree of quadrant involvement,
epithelial appearance (inflammation, ab-
normal vessels, white epithelium, con-
dyloma, mosaicism, leukoplakia, and
punctation), and degree of involvement.
Histologic characteristics of the lesion in-
cluded Papanicolaou smear evaluation,
biopsy, endocervical biopsy, and endo-
cervical curettage koilocytotic atypia.
Among these factors, only mosaicism
was associated with treatment outcome.
Its presence predicted that a lesion would
be less likely to regress (P - .016).
Participant Recruitment and Follow-Up
Three .hundred one patients were ac-
crued and were randomly assigned to
receive their initial 4-day treatment. The
patterns of loss to follow-up were similar
in the two treatment arms (Table 2). At
the primary evaluation point of 15
Table 1. Patient characteristics
Characteristic
Age,y
<24
25-29
>30
Ethnicity
Non-Hispanic white
Hispanic white
Other
Birth-control method
Oral contraceptives
Other
None
Birth control
Barrier
Nonbarrier
Unspecified other
Prior treatment
No
Yes
Placebo*
69
38
44
113
32
6
83
61
7
29
121
1
134
17
RA"
57
41
53
114
24
12
69
62
9
28
118
4
134
16
* Values = number of patients.
Table 2. Participant follow-up and loss*
Duration in the
study, mo
Randomization
3
6
9
12
15
21
27
Placebo
Seen
151
130
97
60
63
81
25
25
Lost
_
20
52
56
59
64
118
126
RA
Seen
150
133
107
63
70
88
23
21
Losi
_
16
39
48
50
56
123
129
*Seen = participants were seen at that particular
follow-up. Lost = participants were not seen at that
particular follow-up and were never seen again. If a
participant did not attend an earlier follow-up, then
reappeared at a later date, she is not included in
either the "seen" or "lost" columns.
months, 81 participants remained in the
placebo group and 88 in the RA treatment
group.
Comparison of End Point to Entry
Biopsy
Biopsy results at the end of the trial
were compared with those at study entry
(Table 3). For the patients with moderate
dysplasia, 32 (43%) demonstrated com-
plete regression by biopsy in the treat-
ment arm compared with 18 (27%) in the
placebo arm (/> = .041). In contrast, no
treatment effect was evident for patients
with severe dysplasia.
We used the logistic regression model
including treatment, quadrant, age, age
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Table 3. Comparison of end point to entry biopsy Table 4. Adverse local events during initial 4-day medication administration*
in panicipanis wim LIIM
Dysplasia Intervention Regression*
Moderate RA 32 (43%)
Placebo 18 (27%)
Severe RA 10 (25%)
Placebo 16(31%)
•Regression = complete biopsy response
Othert
43
48
30
35
(or en-
docervical curettage if biopsy not available) at 15,9,
12, 21, or 27 months as defined in the text.
P = .041 for moderate dysplasia and P =
severe dysplasia.
fOther = no response or CIN upstaged.
by quadrant, treatment by age, and
.33 for
treat-
Event
Cervical
Inflammation
Vascularity
Vaginal inflammation
Vaginal
Burning
Itching
Irritation
Discharge
Vulva
Burning
Itching
Irritation
Placebo,
0
9
2
•i
1
3
4
44(14,10)
1
4
3
mo in the studyt
3
5
1
j
1
1 (1,0)
0 (2,0)
18(20,8)
0
1
1
6
4
0
1
0
0
0
10(13,5)
0
1
0
RA, mo in the studyt
0
28
5
in
5 (3,0)
6(4,0)
9 (5,0)
32(26,14)
13(9,3)
11(9,1)
13(10,3)
3
5
1
2
1
2
1
26(13,4)
0
2(1,0)
2(1,0)
6
2
0
1
1
1
2(0,1)
13(11,3)
4
2
4
ment by quadrant. All adjustment factors
were statistically significant (P<. 10),
with a significant treatment difference (P
= .002).
Toxic Effects
No systemic side effects were seen by
participants. Local adverse events ex-
perienced by the participants during the
initial 4-day treatment phase are shown in
Table 4. These side effects were recorded
as occurring during the treatment periods,
in general during the application of the
medication or after completing the initial
4-day (0-month) treatment. These side ef-
fects were mild for the most part and did
not result in study discontinuation. There
was slightly greater colposcopically de-
termined cervical inflammation reported
in the RA treatment group (P = .001), but
this was clinically not significant. There
was also a higher instance of vaginal in-
flammation at time 0, but this was not as
significant (P = .01). In both arms, there
was an increased vaginal discharge in a
substantial number of the patients. This
discharge was equivalent in the two treat-
ment arms and therefore likely due to the
placebo cream. This side effect was not
dose limiting. The only significant dif-
ference in toxic effects between the two
groups was increased vulva burning, itch-
ing, and irritation during the initial treat-
ment (P = .001). Local adverse side effects
during the maintenance phase were uncom-
mon and mild (data not shown).
Discussion
This study suggests that locally applied
RA may favorably alter the natural his-
tory of CIN if the lesion has not pro-
*Table shows the side effects as categorical yes/no.
tNumbers in columns represent the number of patients with the designated toxicity during the initial 4-day
treatment. Number of patients with greater than mild toxicity is shown in parentheses (moderate, severe).
gressed too far. In patients with CIN II,
there was a greater than 50% increase in
the biopsy-proven complete regression
rate in the RA treatment arm compared
with the placebo arm. No such differen-
ces were evident in patients with severe
dysplasia. Although these effects were
modest, these changes represent the first
time that any therapeutic medication has
been shown in a randomized trial to alter
the natural history of CIN. What might be
the biologic basis for such an effect?
RA has been demonstrated to be an
effective inhibitor of growth and a stimu-
lator of differentiation in many epithelial
and nonepithelial tissues, including cervi-
cal tissues (7). In randomized trials, clini-
cal studies (13,16) have also demon-
strated that malignant secondary recurren-
ces in patients with upper aerodigestive
malignancies or in patients with early
lung cancer can be inhibited by oral 13-
c/j-retinoic acid or retinol, respectively.
There has also been an encouraging ex-
perience with retinoids and carotenoids in
the treatment of oral precancer, a lesion
somewhat similar to that seen in the cer-
vix (17). A number of studies (18) have
shown clinical activity against oral leuko-
plakia, and a large randomized trial has
demonstrated efficacy in a phase III trial
for relatively high-dose 13-c/5'-retinoic
acid. The effect seen may reflect a
generalized response of early disease to a
differentiation agent.
Can biologic studies provide us with
insight into the activity of RA in CIN?
Several different pathways may be in-
volved, (a) Human papillomavirus (HPV)
has been shown to be involved in the
development of CIN and cervical car-
cinoma (14), and RA markedly decreases
the HPV-immortalized rate of human
keratinocytes and decreases production of
E6 and E7 (19); (b) vitamin A deficiency
produces a series of abnormalities of
keratin expression in mouse cervical epi-
thelium (75); and (c) RA induces secre-
tion of latent transforming growth factor
Pi and P2 ' n normal and HPV type 16-
immortalized keratinocytes (20). RA may
well be effecting its response via a num-
ber of different mechanisms. Further
detailing of the interactions of vitamin A,
RA, and cervical keratinocytes should be
informative.
How is RA effecting its response?
Vitamin A can produce innumerable bio-
logic effects on cells, including indirect
immunologic and inflammatory responses
and direct and indirect biochemical
responses. Many of the responses were
accompanied by inflammation. However,
only CIN II and not severe dysplasia
responded in the current trial. If the
response had been effected chemically,
then CIN III should have responded as
well. Nuclear retinoic acid receptors have
been recognized as the natural Iigand for
RA, the proximate metabolite of vitamin
A and the natural effector of vitamin A
action (21). This finding suggests that RA
may cause many of its effects through
modulation of a transcription signal, but
the role of RA receptors in transcriptional
control of cervical cells is unexplored.
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Why is the complete response rate in 
the placebo group so high (27% for mod­
erate dysplasia; 31 % for severe dys­
plasia)? In planning for sample-size 
calculations for the phase III trial, we an­
ticipated that a "spontaneous remission 
rate" between 15% and 20% might occur, 
based on a prior extensive literature 
review. We also recognized that the pla­
cebo cream itself might induce or en­
hance responses, particularly since the 
butylated hydroxytoluene contained in 
the cream is a known chemopreventive 
agent. 
Why did CIN II, but not severe dys­
plasia, respond to the RA? Our presump­
tion is that CIN represents a continuum 
and that with further progression the tis­
sue and/or cells in the lesion become less 
responsive. This predicts that CIN I 
would be responsive to RA. We do not 
know, but because of the low risk of CIN 
I and its high spontaneous regression rate 
and the teratogenicity of RA, the premise 
would be difficult to test. Also, we would 
predict that RA should be ineffective 
against malignant disease. However, 13-
cis-retinoic acid combined with interferon 
a appears to be effective against cervical 
cancer (22). An understanding of why 
this might be so would be quite informa­
tive. 
What is the next step? Further testing 
of RA would not seem warranted. Prac­
titioners will need to decide the clinical 
indications vis-a-vis the risk or benefit for 
RA and CIN. The testing of less toxic 
agents would seem worthwhile. Folic 
acid has been tested in a phase III trial 
and found to be ineffective (Chu J: per­
sonal communication). An impressive 
amount of epidemiologic data suggests 
that both beta carotene and vitamin C 
protect against CIN (23). Trials of these 
agents are ongoing. Also a non-terato­
genic retinoid (oral) 4-hydroxyphenyl­
retinamide has produced responses in oral 
leukoplakia (24), and several studies in 
CIN are now being conducted. Results 
from these trials are eagerly anticipated. 
The results of the current trial provide 
further evidence for the feasibility and ef­
ficacy of chemoprevention trials in epi­
thelial malignancies. The series of studies 
leading to the results presented here have 
spanned over 14 years. We can anticipate 
that advances in the future will proceed 
more rapidly. 
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